🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Michael R. Harrison

Duke University

ORCID: 0000-0003-3776-8892

Also affiliated with Pfizer (United States), Cancer Institute (WIA), Prostate Cancer Research, Duke Medical Center, Duke Cancer Institute, Quest Diagnostics (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer”.

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Cancer(2020)10.1002/cncr.33067

N/A

0.538DataRank · unranked

35 citations

Michael R. Harrison, Peter H. O’Donnell, Ajjai Alva, Noah M. Hahn, Leonard J. Appleman +17 more

Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer

Nature Communications(2024)10.1038/s41467-024-48480-1

N/A

0.510DataRank · unranked

29 citations

Mi Zhou, Jin Seok Lee, Steven Vensko, Mark G. Woodcock, Hsing‐Hui Wang +14 more

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Cancers(2022)10.3390/cancers14153830

N/A

0.442DataRank · unranked

18 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy

JCI Insight(2025)10.1172/jci.insight.185963

N/A

0.269DataRank · unranked

5 citations

Eda K. Holl, Yuan Wu, Anika Agarwal, Mark D. Starr, M. Martinez +7 more

Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.396

N/A

0DataRank · unranked

8 citations

Michael R. Harrison, Allison M. Deal, Chelsea K. Osterman, Sundhar Ramalingam, Young E. Whang +12 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4527

N/A

0DataRank · unranked

2 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001792

N/A

0DataRank · unranked

115 citations

Matthew D. Tucker, Ramy Sedhom, Eric Schwartz, Jason Zhu, Chester Kao +12 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more